Other Events ·
Radiopharm Theranostics reported positive Phase 2b results for its imaging agent RAD 101, with 93% of evaluable…
RADXRadiopharm Theranostics Ltd
Radiopharm Theranostics reported positive Phase 2b results for its imaging agent RAD 101, with 93% of evaluable patients achieving the primary endpoint concordance with MRI. The company plans to initiate a Phase 3 registrational trial in Q4 2026, supported by a manufacturing partnership with Siemens Healthineers. Additionally, early clinical data for therapeutic candidate RAD 204 showed a RECIST-confirmed partial response in the third cohort. Post-quarter end, Radiopharm raised approximately $12.5 million through an institutional offer and launched a $6 million Share Purchase Plan, which was subscribed to up to $3 million. The company also received a $5.9 million Australian R&D Tax Incentive. Cash reserves decreased to $4.1 million at the end of the quarter ended June 30, 2026. Radiopharm Theranostics is a clinical-stage biopharmaceutical company developing innovative oncology radiopharmaceuticals for diagnostic and therapeutic applications.